Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
News Focus
LQWD Technologies Lightning Network Infrastructure Surpasses 1 Million Global Transactions (click to learn more)
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Verrica Pharmaceuticals Inc VRCA

Healthcare
Verrica Pharmaceuticals Inc. is a dermatology therapeutics company. The Company is focused on developing and commercializing treatments for skin diseases. Its product pipeline consists of three product candidates: YCANTH, VP-315 and VP-103. YCANTH is a proprietary drug-device combination that contains a GMP-controlled formulation of cantharidin. We are also developing YCANTH for potential... see more

Recent & Breaking News (NDAQ:VRCA)

ROSEN, National Trial Lawyers, Encourages Verrica Pharmaceuticals Inc. Investors with Losses to Secure Counsel Before Important August 5 Deadline in Securities Class Action - VRCA

Newsfile July 27, 2022

SHAREHOLDER ALERT: The Gross Law Firm Notifies Shareholders of Verrica Pharmaceuticals, Inc. of a Class Action Lawsuit and a Lead Plaintiff Deadline of August 5, 2022 - (NASDAQ: VRCA)

PR Newswire July 27, 2022

VRCA ALERT: The Klein Law Firm Announces a Lead Plaintiff Deadline of August 5, 2022 in the Class Action Filed on Behalf of Verrica Pharmaceuticals, Inc. Shareholders

PR Newswire July 26, 2022

FINAL DEADLINE RAPIDLY APPROACHING: The Schall Law Firm Encourages Investors in Verrica Pharmaceuticals Inc. with Losses of $100,000 to Contact the Firm

Accesswire July 26, 2022

Verrica Securities Fraud Class Action Lawsuit Pending: Contact Levi & Korsinsky Before August 5, 2022 to Discuss Your Rights - VRCA

Newsfile July 25, 2022

INVESTOR ACTION ALERT: The Schall Law Firm Encourages Investors in Verrica Pharmaceuticals Inc. with Losses of $100,000 to Contact the Firm

Newsfile July 25, 2022

CLASS ACTION ALERT: The Law Offices of Vincent Wong Remind Verrica Investors of a Lead Plaintiff Deadline of August 5, 2022

PR Newswire July 25, 2022

ROSEN, GLOBAL INVESTOR COUNSEL, Encourages Verrica Pharmaceuticals Inc. Investors With Losses to Secure Counsel Before Important August 5 Deadline in Securities Class Action - VRCA

Newsfile July 24, 2022

ROSEN, RESPECTED INVESTOR COUNSEL, Encourages Verrica Pharmaceuticals Inc. Investors to Secure Counsel Before Important August 5 Deadline in Securities Class Action - VRCA

PR Newswire July 23, 2022

VRCA ALERT: The Klein Law Firm Announces a Lead Plaintiff Deadline of August 5, 2022 in the Class Action Filed on Behalf of Verrica Pharmaceuticals, Inc. Limited Shareholders

Newsfile July 22, 2022

SHAREHOLDER ACTION NOTICE: The Schall Law Firm Encourages Investors in Verrica Pharmaceuticals Inc. with Losses of $100,000 to Contact the Firm

Newsfile July 22, 2022

VRCA SHAREHOLDER ALERT: Jakubowitz Law Reminds Verrica Shareholders of a Lead Plaintiff Deadline of August 5, 2022

PR Newswire July 22, 2022

Verrica Class Action: Levi & Korsinsky Reminds Verrica Pharmaceuticals, Inc. Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of August 5, 2022 - VRCA

Newsfile July 21, 2022

SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Verrica Pharmaceuticals, Inc. -VRCA

PR Newswire July 21, 2022

VRCA LAWSUIT ALERT: Levi & Korsinsky Notifies Verrica Pharmaceuticals, Inc. Investors of a Class Action Lawsuit and Upcoming Deadline

PR Newswire July 21, 2022

ROSEN, National Trial Lawyers, Encourages Verrica Pharmaceuticals Inc. Investors with Losses to Secure Counsel Before Important Deadline in Securities Class Action - VRCA

Newsfile July 20, 2022

Berger Montague Investigates Securities Fraud Allegations Against Verrica Pharmaceuticals, Inc. (NASDAQ: VRCA) - VERRICA PHARMACEUTICALS, INC. - Lead Plaintiff Deadline is August 5, 2022

PR Newswire July 20, 2022

SHAREHOLDER ACTION REMINDER: The Schall Law Firm Encourages Investors in Verrica Pharmaceuticals Inc. with Losses of $100,000 to Contact the Firm

Newsfile July 20, 2022

SHAREHOLDER ALERT: The Gross Law Firm Notifies Shareholders of Verrica Pharmaceuticals, Inc. of a Class Action Lawsuit and a Lead Plaintiff Deadline of August 5, 2022 - (NASDAQ: VRCA)

PR Newswire July 20, 2022

SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of Verrica Pharmaceuticals, Inc. -VRCA

Newsfile July 19, 2022